Asset profile
Ambroxol
Small molecule
Evidence outlook · registrational
Parkinson's Disease: registrational readout pending
Entered Phase 3 on partial signal mid-stage evidence. Registrational readout expected around 2029-02.
NCT05287503: The trial randomized 65 participants to ambroxol or placebo with participants, care providers, investigators, and outcome assessors masked. Its primary outcomes were clinical cognitive measures, but the comparison cannot yet be judged because results are not posted, so the evidence remains limited rather than strong.
Source is the AMBITIOUS trial preprint (SSRN, not yet peer reviewed); the quote was transcribed from indexed renderings of the abstract because the SSRN page blocks automated retrieval. The direction of the result and the companion levodopa-equivalent figure are corroborated by independent renderings.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.
2029 (1)
February 2029 (1)
What to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access ResearchAll registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.